Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00254
|
|||||
| Drug Name |
Sitagliptin
|
|||||
| Synonyms |
(2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE; (3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; Janumet; Januvia; Januvia (TN); Januvia (merck & Co.); MK-0431; Sitagliptan; Sitagliptin (Prop.INN); Sitagliptin phosphate; Xelevia
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Type 2 diabetes [ICD11: 5A11] | Approved | [1] | |||
| Therapeutic Class |
Hypoglycemic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C16H15F6N5O
|
|||||
| Canonical SMILES |
C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)CC(CC3=CC(=C(C=C3F)F)F)N
|
|||||
| InChI |
InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1
|
|||||
| InChIKey |
MFFMDFFZMYYVKS-SECBINFHSA-N
|
|||||
| CAS Number |
CAS 486460-32-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 407.31 | Topological Polar Surface Area | 77 | ||
| Heavy Atom Count | 28 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 10 | |||
| XLogP |
0.7
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103502876
, 112947540
, 117695427
, 126669712
, 126731480
, 134337929
, 135206675
, 136339733
, 137005783
, 143037551
, 143497677
, 14904024
, 152028143
, 152164204
, 152164205
, 152238548
, 152344340
, 160646743
, 160964592
, 162201432
, 16466401
, 164784279
, 164824529
, 164846813
, 165235282
, 165245552
, 165702336
, 170499559
, 174006349
, 174529510
, 175268642
, 178102906
, 179231014
, 186005103
, 35668584
, 46393524
, 46505822
, 46511716
, 46513917
, 46530623
, 48034814
, 50070925
, 56365842
, 78231257
, 7885474
, 85789641
, 92307950
, 96025201
, 9656038
, 99443685
|
|||||
| ChEBI ID |
ChEBI:40237
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [2] | |
| OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [3] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [4] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | OAT3 | Transporter Info | Km = 162 microM | Chinese hamster ovary (CHO) cells-OAT3 | [2] | |
| References | ||||||
| 1 | Sitagliptin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther. 2007 May;321(2):673-83. | |||||
| 3 | 265 effect of dietary cholesterol on gallbladder bile lithogenicity and gene expression in the enterohepatic axis of non-obese gallstone and control women. Journal of Hepatology, 2009, 50(09):S105-S106. | |||||
| 4 | Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.